{"id":"etavopivat-b","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Gout"},{"rate":null,"effect":"Elevated uric acid levels"}]},"_chembl":{"chemblId":"CHEMBL4650332","moleculeType":"Small molecule","molecularWeight":"457.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etavopivat is a pyruvate dehydrogenase kinase inhibitor that increases pyruvate dehydrogenase activity, leading to increased acetyl-CoA production and enhanced ATP generation in red blood cells. This metabolic shift reduces sickling and hemolysis by improving red blood cell resilience and decreasing vaso-occlusive crises in patients with sickle cell disease.","oneSentence":"Etavopivat activates the pyruvate dehydrogenase kinase (PDK) inhibitor pathway to reduce hemolysis in sickle cell disease by modulating red blood cell metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:43.420Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sickle cell disease (vaso-occlusive crises and hemolysis reduction)"}]},"trialDetails":[{"nctId":"NCT06609226","phase":"PHASE3","title":"A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-01-10","conditions":"Sickle Cell Disease, Thalassemia","enrollment":480},{"nctId":"NCT07023029","phase":"PHASE1","title":"A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2025-06-09","conditions":"Healthy Volunteers, Sickle Cell Disease, Thalassemia","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Etavopivat B","genericName":"Etavopivat B","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etavopivat activates the pyruvate dehydrogenase kinase (PDK) inhibitor pathway to reduce hemolysis in sickle cell disease by modulating red blood cell metabolism. Used for Sickle cell disease (vaso-occlusive crises and hemolysis reduction).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}